Detalhe da pesquisa
1.
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
N Engl J Med
; 388(11): 1002-1014, 2023 Mar 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36762851
2.
Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001.
Blood
; 143(5): 404-416, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37890149
3.
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study.
Blood
; 141(14): 1675-1684, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36542826
4.
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.
Lancet
; 402(10402): 641-654, 2023 08 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37295445
5.
HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide.
Blood
; 139(10): 1452-1468, 2022 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34724567
6.
Plain language summary of the TRANSFORM study primary analysis results: lisocabtagene maraleucel as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen.
Future Oncol
; 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38547003
7.
Plain Language Summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma.
Future Oncol
; 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38651976
8.
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
Lancet
; 399(10343): 2294-2308, 2022 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35717989
9.
HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis.
Blood
; 138(3): 273-282, 2021 07 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34292325
10.
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.
Lancet Oncol
; 23(8): 1066-1077, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35839786
11.
Inferences for current chronic graft-versus-host-disease free and relapse free survival.
BMC Med Res Methodol
; 22(1): 318, 2022 12 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36513966
12.
Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS).
Cancer
; 127(23): 4421-4431, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34424530
13.
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Lancet
; 396(10254): 839-852, 2020 09 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-32888407
14.
Differences in Graft-versus-Host Disease Characteristics between Haploidentical Transplantation Using Post-Transplantation Cyclophosphamide and Matched Unrelated Donor Transplantation Using Calcineurin Inhibitors.
Biol Blood Marrow Transplant
; 26(11): 2082-2088, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32745575
15.
Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant.
Biol Blood Marrow Transplant
; 26(10): 1930-1936, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32649981
16.
Fludarabine and Total-Body Irradiation Conditioning before Ablative Haploidentical Transplantation: Long-Term Safety and Efficacy.
Biol Blood Marrow Transplant
; 25(11): 2211-2216, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31247313
17.
Who Is a Better Donor for Recipients of Allogeneic Hematopoietic Cell Transplantation: A Young HLA-Mismatched Haploidentical Relative or an Older Fully HLA-Matched Sibling or Unrelated Donor?
Biol Blood Marrow Transplant
; 25(10): 2054-2060, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31173900
18.
The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant
; 25(3): 606-612, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30244109
19.
Superior Survival of Black Versus White Patients Following Post-Transplant Cyclophosphamide-Based Haploidentical Transplantation for Adults with Hematologic Malignancy.
Biol Blood Marrow Transplant
; 24(6): 1237-1242, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29378303
20.
Selecting the Best Donor for Haploidentical Transplant: Impact of HLA, Killer Cell Immunoglobulin-Like Receptor Genotyping, and Other Clinical Variables.
Biol Blood Marrow Transplant
; 24(4): 789-798, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29355721